tt2015

Targeting Trends 2015 Newsletter

Read the 2015 Newsletters and recent scientific references 2015, issue 1: Impairments in gait, posture and complex movement control in rats modeling the multi-system, cholinergic-dopaminergic losses in Parkinson’s Disease / by Aaron Kucinski / featuring 192-IgG-SAP (Cat. #IT-01), Anti-ChAT-SAP (Cat. #IT-42) Society for Neuroscience Poster of the Year Award Veterinary Development of Substance P-Saporin (SP-SAP) Targeting Talk: […]

Targeting Trends 2015 Newsletter Read More »

Targeting Tools: MonoBiotin-ZAP

The conjugation specialists at Advanced Targeting Systems are proud to announce a new addition to the catalog: MonoBiotin-ZAP Cat. #BT-ZAP Researchers now have more freedom in selecting conjugation strategies. Users have taken advantage of the ability to use biotinylated targeting agents with Streptavidin-ZAP (Cat. #IT-27) a chemical conjugate between saporin and streptavidin. Streptavidin-ZAP converts biotinylated

Targeting Tools: MonoBiotin-ZAP Read More »

Targeting Tools: Anti-ChAT-SAP

Choline acetyltransferase (ChAT) catalyzes the synthesis of the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA in cholinergic neurons. ChAT serves as a specific marker for cholinergic neurons in both peripheral and central nervous systems. Evidence shows that ChAT exists in two forms inside cholinergic nerve terminals, a soluble hydrophilic form and the membrane-associated amphiphilic form.[1-2]

Targeting Tools: Anti-ChAT-SAP Read More »

Cover Article: Anti-ChAT-SAP elucidates a causal role in behavioral flexibility

A specific immunotoxin elucidates a causal role of striatal cholinergic system in behavioral flexibility by Sho Aoki and Jeffery R. Wickens Neurobiology Research Unit, Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna, Kunigami, Okinawa 904-0495, Japan Behavioral flexibility is broadly defined as the ability to change behavioral strategy, according to a change of governing

Cover Article: Anti-ChAT-SAP elucidates a causal role in behavioral flexibility Read More »

Cover Article: SP-SAP Human Clinical Trial for Cancer Pain – An Anesthesiologist’s Point of View

by Carl Noe, M.D., Anesthesiology & Pain Management, UT Southwestern Medical Center, Dallas, TX; and Eugene McDermott Center for Pain Management, Dallas, Texas Dr. Noe is the Principal Investigator in the ongoing trial of SP-SAP Intrathecal SP-SAP (Substance P attached to the ribosome-inactivating protein, saporin) has been studied in a Phase 1 clinical trial of

Cover Article: SP-SAP Human Clinical Trial for Cancer Pain – An Anesthesiologist’s Point of View Read More »

Cover Article: Drug-free selection of stable transfectants using targeted toxin technology and a vector expressing cell-surface carbohydrate-digesting enzyme

by Masahiro Sato1 (Ph. D.) and Satoshi Watanabe2 (Ph. D.) 1Section of Gene Expression Regulation, Frontier Science Research Center, Kagoshima University, Kagoshima 890-8544, Japan: 2Animal Genome Research Unit, Division of Animal Science, National Institute of Agrobiological Sciences, Ibaraki 305-8602, Japan Isolation of stable transfectants is one of the important steps for exploring biological functions of

Cover Article: Drug-free selection of stable transfectants using targeted toxin technology and a vector expressing cell-surface carbohydrate-digesting enzyme Read More »

Targeting Tools: ZAP SrB Development Kit

The ZAP Sulforhodamine B (SrB; Cat. #KIT-SrB-Z) Development kit contains all of the materials needed to introduce a quantitative staining assay to your lab. Preferred by the National Cancer Institute for high-throughput drug screening, SrB quantitatively stains cellular proteins in an accurate and reproducible manner. Refined and honed over years of use in testing Saporin-conjugate

Targeting Tools: ZAP SrB Development Kit Read More »

Veterinary Development of Substance P-Saporin (SP-SAP)

A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon

Veterinary Development of Substance P-Saporin (SP-SAP) Read More »

Shopping Cart
Scroll to Top